Literature DB >> 10737702

Metabolism and effect of platelet-activating factor on the growth of human myeloma cell lines.

V Desplat1, C Dulery, J L Faucher, V Praloran, Y Denizot.   

Abstract

In this study we have investigated the presence of PAF receptor (PAF-R) on 5 myeloma cell lines (U266, L363, IM9, OPM2 and XG1), their metabolism of PAF and lyso PAF, and the effect of PAF on their growth. All myeloma cell lines express a PAF acetylhydrolase activity and metabolize [3H]PAF and [3H]lyso PAF in 1-alkyl-2-acyl analogue of phosphatidylcholine. Polymerase chain reaction on reverse transcript (RT-PCR) experiments indicate that OPM2, U266, IM9, XG1 and L363 cells express the PAF-R transcript 1 but not the PAF-R transcript 2. Flow cytometry experiments reveal that PAF-R are present on these myeloma cell lines. PAF and the non-metabolizable PAF agonist 1-O-hexadecyl-2-N-methycarbamyl-glycero-3-phosphocholine have no effect on the growth of OPM2, U266, IM9, XG1 and L363 assessed by [3H]thymidine incorporation into DNA. As a positive control of PAF effect on myeloma cells, PAF (1 microM) enhances by 100% the immunoglobulin synthesis by IM9 cells cultured for 48 h. In conclusion the five myeloma cell lines used in this study metabolize PAF through the deacetylation/reacylation pathway. They express membrane PAF-R through the PAF-R mRNA transcript 1 but PAF does not affect their growth.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737702     DOI: 10.1016/s0304-3835(99)00295-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  Expression of a splice variant of the platelet-activating factor receptor transcript 2 in various human cancer cell lines.

Authors:  Ibtissam Youlyouz; Emmanuelle Magnoux; Laurence Guglielmi; Yves Denizot
Journal:  Mediators Inflamm       Date:  2002-10       Impact factor: 4.711

2.  Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.

Authors:  Keiko Maekawa; Masaki Ri; Miki Nakajima; Akihiro Sekine; Ryuzo Ueda; Masahiro Tohkin; Naoki Miyata; Yoshiro Saito; Shinsuke Iida
Journal:  Cancer Sci       Date:  2019-09-19       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.